Evidence map›Paper›PMID 40809424›Full record

ArticleFrontiers in medicine2025

A roadmap for personalized medicine: the findings of the IC2PerMed project.

Flavia Beccia, Francesco Andrea Causio, Marzia Di Marcantonio, Ilda Hoxhaj, Chiara Cadeddu, Melissa Campagno, Lena Schleicher, Carmen Fotino, Maike Tauchert, Marta Lomazzi and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Flavia BecciaSection of Hygiene, Department of Life Sciences and Public Health, Università Cattolica del Sacro Cuore, Rome, Italy.
Francesco Andrea CausioSection of Hygiene, Department of Life Sciences and Public Health, Università Cattolica del Sacro Cuore, Rome, Italy.
Marzia Di MarcantonioFaculty of Economics, Università Cattolica del Sacro Cuore, Rome, Italy.
Ilda HoxhajDepartment of Medical and Surgical Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
Chiara CadedduErasmus School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, Netherlands.
Melissa CampagnoG.A.C. Group - Innovation and Performance for Impact, Valbonne, France.
Lena SchleicherSteinbeis Europa Zentrum (SEZ), Stuttgart, Germany.
Carmen FotinoFondazione Telethon, Milan, Italy.
Maike TauchertBBMRI-ERIC, Graz, Austria.
Marta LomazziWorld Federation of Public Health Associations (WFPHA), Geneva, Switzerland.
Lili WangJingyi Alliance Clinical Application; BGI, Beijing, China.
Wenya WangCenter of Biotherapy, Beijing Tsinghua Changgang Hospital, Tsinghua University, Beijing, China.
Huiyao HuangAcademic Director, Clinical Trials Center of National Cancer Center, Beijing, China.
Walter RicciardiSection of Hygiene, Department of Life Sciences and Public Health, Università Cattolica del Sacro Cuore, Rome, Italy.
Stefania BocciaSection of Hygiene, Department of Life Sciences and Public Health, Università Cattolica del Sacro Cuore, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Personalized Medicine (PM) tailors prevention and treatment to individuals based on their unique characteristics. It has the potential to improve health outcomes and healthcare sustainability by optimizing resource allocation. Both the European Union (EU) and China have prioritized PM in their health strategies. The IC2PerMed project was established to foster collaboration between the EU and China by developing a joint PM roadmap. Methods: To assess the state of PM in the EU and China, the project conducted a comprehensive mapping of relevant policies, programs, funding mechanisms, and health ecosystems. Additionally, three Delphi surveys were carried out, identifying 65 priorities, which were synthesized into a set of strategic actions. Results: The main output of the project is a joint roadmap for implementing PM in the EU and China. The roadmap promotes best practice exchange and addresses potential barriers to PM adoption. It outlines structural actions including enhancing health literacy, fostering intersectoral and international collaboration, ongoing review of emerging technologies, and facilitating innovation market entry through needs assessment and Health Technology Assessment. Key enablers such as data interoperability and shared standards are highlighted, along with ethical, social, and regulatory considerations that are universally relevant to PM implementation. Discussion: A shared action plan can guide health policy and help policymakers understand the interconnection between healthcare, the economy, and society. By supporting international projects and investing in research and innovation, stakeholders can advance global healthcare.

Indexed as

ChinaEuropean Unionpersonalized medicineprioritiesroadmap

Identifiers

PMID40809424
PMCPMC12343625

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.